Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190891 | 0.86 | RIPK1 (0.49) | KMT2ASMN1; SMN2RIPK1KDM4EALDH1A1 | |
| SCHEMBL12775941 | 0.84 | SMN1; SMN2 (0.51) | KMT2ASMN1; SMN2RIPK1ALDH1A1BCHE | |
| SCHEMBL7559310 | 0.82 | KMT2A (0.53) | KMT2ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL2518861 | 0.80 | SMN1; SMN2 (0.68) | KMT2ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL16953073 | 0.79 | KMT2A (0.51) | KMT2ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL29175409 | 0.79 | SMN1; SMN2 (0.48) | KMT2ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL12844409 | 0.79 | SMN1; SMN2 (0.48) | KMT2ASMN1; SMN2KDM4EALDH1A1BCHE | |
| SCHEMBL10190866 | 0.77 | RIPK1 (0.62) | KMT2ARIPK1KDM4EALDH1A1TP53 | |
| SCHEMBL1254107 | 0.77 | KMT2A (0.55) | KMT2ASMN1; SMN2KDM4EALDH1A1BCHE | |
| SCHEMBL1254108 | 0.77 | TAAR1 (0.61) | KMT2ASMN1; SMN2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | KMT2A 2987/4885SMN1; SMN2 1371/4885RIPK1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.